Cite
MLA Citation
Nicolas Duveau et al.. “Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.” Digestive and liver disease, vol. 49, no. 2, 2017, pp. 163–169. http://access.bl.uk/ark:/81055/vdc_100040979327.0x00000a